Riociguat API

Name	Riociguat
Chinese name	利奥西呱
Cas Number	625115-55-1
Source	India
Qualifications	USDMF/-/-/-/-

Lioxigar is a soluble guanylate cyclase activator developed by Bayer in Germany. It is an important signaling enzyme that can be activated by nitric oxide (NO) to catalyze the conversion of guanosine triphosphate (GTP) It is the second messenger cyclic guanosine phosphate (cGMP), the first drug of any category approved by the FDA as a drug category for the treatment of pulmonary hypertension and the first drug of any category that has been shown to be effective for patients with chronic thromboembolic pulmonary hypertension (CTEPH). The first and only therapeutic drug approved for CTEPH in the EU. Compared with bosentan, the safety and tolerability of the treatment of chronic thromboembolic pulmonary hypertension with lioxigua are better. Clinical studies have shown that Lyoxigarate is not only effective in the treatment of pulmonary hypertension, but also easy to tolerate, with mild adverse reactions. Its absolute bioavailability is about 94%, and its bioavailability will not be affected by the presence of food after oral administration. . Leo Sigua’s global sales in 2019 were US$456 million, and Cortellis predicts that its sales in 2022 will reach US$1.3 billion.

Hot Tags: riociguat api, China, suppliers, manufacturers, factory, customized, price, pricelist, in stock, Perindopril Arginine API, Bemeprost API, Perindopril Tert butylamine Salt API, Pabxilib API, Salmeterol Xinafoate API, Edoxaban API

• Previous: Apixaban API
• Next: Benzoyl Peroxide API